OrthoPediatrics Corp. (“OrthoPediatrics” or the
“Company”) (Nasdaq: KIDS), a company focused exclusively on
advancing the field of pediatric orthopedics, today announced its
financial results for the second quarter ended June 30, 2023.
Second Quarter
2023 and Business Highlights
- Helped over 21,000 children in the
second quarter of 2023, bringing the total to over 670,000 since
inception including MD Orthopaedics ("MD Ortho") and Pega
Medical
- Generated total revenue of $39.6
million for the second quarter of 2023, up 20% from $32.9 million
in second quarter 2022; domestic revenue increased 19% and
international revenue increased 25% in the quarter
- Grew Trauma & Deformity revenue
22%, Scoliosis revenue 16%; Sports Medicine/Other revenue 23%,
worldwide in the second quarter of 2023 compared to the second
quarter of 2022
- Consigned $9.2 million of sets in
the second quarter of 2023 compared to $3.4 million in the second
quarter of 2022, and $3.0 million in the first quarter of 2023,
driven by new product development deployments, significant Pega
Medical deployments and the consignment of multiple 7D Surgical
FLASH Navigation Platforms
- Launched the GIRO Growth Modulation
System, for the correction of angular deformities of long bones and
limb length discrepancy, the first new Pega Medical system to
receive FDA clearance and be launched under OrthoPediatrics
- Reiterated full year 2023 revenue
guidance of $148.0 million to $151.0 million, representing growth
of 21% to 23% compared to the prior year
David Bailey, President & CEO of
OrthoPediatrics, commented, “I am pleased with our execution across
the business in the second quarter. Strong commercial and
operational performances drove robust revenue growth and improved
operating leverage as we observed gradual month-by-month
improvements within the children’s hospitals inpatient surgical
environment. Looking ahead, we are favorably positioned for the
second half of the year as new product development and launches,
set consignments, 7D system placements and prolific surgeon
training and education, support adoption and further share gains
for OrthoPediatrics.”
Second Quarter
2023 Financial ResultsTotal
revenue for the second quarter of 2023 was $39.6 million, a 20%
increase compared to $32.9 million for the same period last year.
U.S. revenue for the second quarter of 2023 was $29.6 million, a
19% increase compared to $25.0 million for the same period last
year, representing 75% of total revenue. The increase in U.S.
revenue in the second quarter of 2023 was driven primarily by
continued share gains across the legacy portfolio, Pega Medical
contributions, and growth of the non-surgical specialty bracing
business. International revenue for the second quarter of 2023 was
$10.0 million, a 25% increase compared to $8.0 million for the same
period last year, representing 25% of total revenue. International
growth in the quarter was primarily driven by strong performance
with the Scoliosis products as well as the Trauma and Deformity
products lines, including non-surgical bracing.
Trauma and Deformity revenue for the second
quarter of 2023 was $27.5 million, a 22% increase compared to $22.6
million for the same period last year. This growth was driven
primarily by share gains across the entire portfolio, with strong
contributions from Deformity Correction. Scoliosis revenue was
$10.9 million, a 16% increase compared to $9.4 million for the
second quarter of 2022. This growth was driven primarily by the
combined strength of ApiFix, Response, and 7D. Sports
Medicine/Other revenue for the second quarter of 2023 was $1.2
million, a 23% increase compared to $0.9 million for the same
period last year.
Gross profit for the second quarter of 2023 was $30.0 million, a
20% increase compared to $25.0 million for the same period last
year. Gross profit margin for the second quarter of 2023 was 76%,
flat compared to 76% for the same period last year.
Total operating expenses for the second quarter
of 2023 were $35.6 million, a 24% increase compared to $28.7
million for the same period last year. The increase was mainly
driven by incremental personnel related expenses required to
support the ongoing growth of the company as well as increased
sales and marketing expenses driven by the increase in revenue.
Sales and marketing expenses increased $0.7
million, or 6%, to $13.2 million in the second quarter of 2023. The
increase was driven primarily by increased sales commission
expenses.
General and administrative expenses increased
$5.1 million, or 35%, to $19.7 million in the second quarter of
2023. The increase was driven primarily by an increase in non-cash
G&A expenses including depreciation, amortization and
stock-based compensation as well as additional personnel related
expenses required to support the ongoing growth of the company.
Total other income was $2.3 million for the
second quarter of 2023, compared to $3.0 million for the same
period last year. The change was due primarily to the fair value
adjustment of contingent consideration, which was driven by the
valuation inputs that were lower in comparison to the same period
last year.
Net loss for the second quarter of 2023 was $2.9
million, compared to $0.3 million for the same period last year.
Net loss per share for the period was $0.13 per basic and diluted
share, compared to $0.02 per basic and diluted share for the same
period last year.
Adjusted EBITDA for the second quarter of 2023
was $2.3 million as compared to $2.1 million for the second quarter
of 2022.
Weighted average basic and diluted shares
outstanding for the three months ended June 30, 2023, was
22,704,723 shares.
As of June 30, 2023, cash, cash
equivalents, short-term investments and restricted cash were $94.8
million compared to $119.8 million and $52.5 million as of
December 31, 2022, and June 30, 2022. Additionally, the
Company had no balance outstanding under the $50.0 million line of
credit.
Full Year 2023
Financial GuidanceFor the full year of 2023, the
Company reiterated its revenue guidance to be in the range of
$148.0 million to $151.0 million, representing growth of 21% to 23%
over 2022 revenue. The Company reiterated its expectations for
annual set deployments of approximately $25.0 million and $3.0
million to $4.0 million of adjusted EBITDA for the full year of
2023.
Conference CallOrthoPediatrics
will host a conference call on Tuesday, August 1, 2023, at 8:00
a.m. ET to discuss the results. Investors interested in listening
to the conference call may do so by accessing a live and archived
webcast of the event at www.orthopediatrics.com, on the Investors
page in the Events & Presentations section. The webcast will be
available for replay for at least 90 days after the event.
Forward-Looking StatementsAll
statements, other than statements of historical facts, contained in
this quarterly report, including statements regarding our business,
operations and financial performance and condition, as well as our
plans, objectives and expectations for our business, operations and
financial performance and condition, are forward-looking
statements. You can often identify forward-looking statements by
words such as "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "might," "target,"
"ongoing," "plan," "potential," "predict," "project," "should,"
"will" or "would," or the negative of these terms or other terms.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors, such as the impact of widespread
health emergencies, such as COVID 19 and respiratory syncytial
virus, that may cause our results, activity levels, performance or
achievements to be materially different from the information
expressed or implied by the forward-looking statements.
Forward-looking statements may include, among other things,
statements relating to: our ability to achieve or sustain
profitability in the future; our ability to raise additional
capital to fund our existing commercial operations, develop and
commercialize new products and expand our operations; our ability
to commercialize our products in development and to develop and
commercialize additional products through our research and
development efforts, and if we fail to do so we may be unable to
compete effectively; our ability to generate sufficient revenue
from the commercialization of our products to achieve and sustain
profitability; our ability to comply with extensive government
regulation and oversight both in the United States and abroad; our
ability to maintain and expand our network of third-party
independent sales agencies and distributors to market and
distribute our products; and our ability to protect our
intellectual property rights or if we are accused of infringing on
the intellectual property rights of others; We cannot assure you
that forward-looking statements will prove to be accurate, and you
are encouraged not to place undue reliance on forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations expressed or implied by the
forward-looking statements. You are urged to carefully review and
consider the various disclosures made by us in this quarterly
report, in our Annual Report on Form 10-K filed with the Securities
and Exchange Commission (the "SEC") on March 1, 2023 and in other
reports filed with the SEC that discuss the risks and factors that
may affect our business. Other than as required by law, we
undertake no obligation to update or revise any forward-looking
statements to reflect new information, events or circumstances
occurring after the date of this quarterly report.
Use of Non-GAAP Financial
MeasuresThis press release includes certain non-GAAP
financial measures such as adjusted diluted earnings (loss) per
share and Adjusted EBITDA, which differ from financial measures
calculated in accordance with U.S. generally accepted accounting
principles (“GAAP”). Adjusted earnings (loss) per share in this
press release represents diluted earnings (loss) per share on a
GAAP basis, plus the accreted interest attributable to acquisition
installment payables, the fair value adjustment of contingent
consideration, trademark impairment, acquisition related costs,
non-recurring professional fees, accrued legal settlement costs and
minimum purchase commitment costs. The fair value adjustment of
contingent consideration is associated with our estimates of the
value of earn-outs in connection with certain acquisitions and the
non-recurring professional fees are related to our response to a
previously disclosed SEC review. We believe that providing the
non-GAAP diluted earnings (loss) per share excluding these
expenses, as well as the GAAP measures, assists our investors
because such expenses are not reflective of our ongoing operating
results. Adjusted EBITDA in this release represents net loss, plus
interest expense, net plus other expense, provision for income
taxes (benefit), depreciation and amortization, stock-based
compensation expense, fair value adjustment of contingent
consideration, acquisition related costs, nonrecurring conversion
fees, and the cost of minimum purchase commitments. The Company
believes the non-GAAP measures provided in this earnings release
enable it to further and more consistently analyze the
period-to-period financial performance of its core business
operating performance. Management uses these metrics as a measure
of the Company’s operating performance and for planning purposes,
including financial projections. The Company believes these
measures are useful to investors as supplemental information
because they are frequently used by analysts, investors and other
interested parties to evaluate companies in its industry. Adjusted
EBITDA is a non-GAAP financial measure and should not be considered
as an alternative to, or superior to, net income or loss as a
measure of financial performance or cash flows from operations as a
measure of liquidity, or any other performance measure derived in
accordance with GAAP, and it should not be construed to imply that
the Company’s future results will be unaffected by unusual or
non-recurring items. In addition, the measure is not intended to be
a measure of free cash flow for management’s discretionary use, as
it does not reflect certain cash requirements such as debt service
requirements, capital expenditures and other cash costs that may
recur in the future. Adjusted EBITDA contains certain other
limitations, including the failure to reflect our cash
expenditures, cash requirements for working capital needs and other
potential cash requirements. In evaluating these non-GAAP measures,
you should be aware that in the future the Company may incur
expenses that are the same or similar to some of the adjustments in
this presentation. The Company’s presentation of non-GAAP diluted
earnings (loss) per share or Adjusted EBITDA should not be
construed to imply that its future results will be unaffected by
any such adjustments. Management compensates for these limitations
by primarily relying on the Company’s GAAP results in addition to
using these adjusted measures on a supplemental basis. The
Company’s definition of these measures is not necessarily
comparable to other similarly titled captions of other companies
due to different methods of calculation. The schedules below
contain reconciliations of reported GAAP diluted earnings (loss)
per share to non-GAAP diluted earnings (loss) and net loss to
non-GAAP Adjusted EBITDA.
About OrthoPediatrics
Corp.Founded in 2006, OrthoPediatrics is an orthopedic
company focused exclusively on advancing the field of pediatric
orthopedics. As such it has developed the most comprehensive
product offering to the pediatric orthopedic market to improve the
lives of children with orthopedic conditions. OrthoPediatrics
currently markets 50 surgical systems that serve three of the
largest categories within the pediatric orthopedic market. This
product offering spans trauma and deformity, scoliosis, and sports
medicine/other procedures. OrthoPediatrics’ global sales
organization is focused exclusively on pediatric orthopedics and
distributes its products in the United States and over 70 countries
outside the United States. For more information, please visit
www.orthopediatrics.com.
Investor ContactPhilip Trip
TaylorGilmartin Groupphilip@gilmartinir.com415-937-5406
ORTHOPEDIATRICS CORP.CONDENSED
CONSOLIDATED BALANCE
SHEETS(Unaudited)(In Thousands,
Except Share Data) |
|
|
June 30, 2023 |
|
December 31, 2022 |
ASSETS |
Current assets: |
|
|
|
|
Cash and cash equivalents |
|
$ |
9,713 |
|
|
$ |
8,991 |
|
Restricted cash |
|
|
1,596 |
|
|
|
1,471 |
|
Short-term investments |
|
|
83,472 |
|
|
|
109,299 |
|
Accounts receivable – trade, net of allowances of $1,097 and
$1,056, respectively |
|
|
33,849 |
|
|
|
24,800 |
|
Inventories, net |
|
|
90,983 |
|
|
|
78,192 |
|
Prepaid expenses and other current assets |
|
|
3,642 |
|
|
|
3,966 |
|
Total current assets |
|
|
223,255 |
|
|
|
226,719 |
|
Property and equipment,
net |
|
|
40,071 |
|
|
|
34,286 |
|
Other assets: |
|
|
|
|
Amortizable intangible assets, net |
|
|
71,932 |
|
|
|
64,980 |
|
Goodwill |
|
|
82,911 |
|
|
|
86,821 |
|
Other intangible assets |
|
|
16,087 |
|
|
|
14,921 |
|
Other non-current assets |
|
|
614 |
|
|
|
— |
|
Total other assets |
|
|
171,544 |
|
|
|
166,722 |
|
Total assets |
|
$ |
434,870 |
|
|
$ |
427,727 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
Current liabilities: |
|
|
|
|
Accounts payable – trade |
|
|
20,890 |
|
|
|
11,150 |
|
Accrued compensation and benefits |
|
|
8,159 |
|
|
|
6,744 |
|
Current portion of long-term debt with affiliate |
|
|
148 |
|
|
|
144 |
|
Current portion of acquisition installment payable |
|
|
9,713 |
|
|
|
7,815 |
|
Other current liabilities |
|
|
5,401 |
|
|
|
5,018 |
|
Total current liabilities |
|
|
44,311 |
|
|
|
30,871 |
|
Long-term liabilities: |
|
|
|
|
Long-term debt with affiliate, net of current portion |
|
|
688 |
|
|
|
763 |
|
Acquisition installment payment, net of current portion |
|
|
3,427 |
|
|
|
8,019 |
|
Contingent consideration |
|
|
6 |
|
|
|
2,980 |
|
Deferred income taxes |
|
|
5,564 |
|
|
|
5,954 |
|
Other long-term liabilities |
|
|
562 |
|
|
|
492 |
|
Total long-term liabilities |
|
|
10,247 |
|
|
|
18,208 |
|
Total liabilities |
|
|
54,558 |
|
|
|
49,079 |
|
Stockholders' equity: |
|
|
|
|
Common stock, $0.00025 par value; 50,000,000 shares authorized;
23,340,463 shares and 22,877,962 shares issued as of June 30,
2023 and December 31, 2022, respectively |
|
|
6 |
|
|
|
6 |
|
Additional paid-in capital |
|
|
574,677 |
|
|
|
560,810 |
|
Accumulated deficit |
|
|
(186,460 |
) |
|
|
(176,768 |
) |
Accumulated other comprehensive loss |
|
|
(7,911 |
) |
|
|
(5,400 |
) |
Total stockholders' equity |
|
|
380,312 |
|
|
|
378,648 |
|
|
|
|
|
|
Total liabilities and
stockholders' equity |
|
$ |
434,870 |
|
|
$ |
427,727 |
|
ORTHOPEDIATRICS CORP.CONDENSED
CONSOLIDATED STATEMENTS OF
OPERATIONS(Unaudited)(In
Thousands, Except Share and Per Share Data) |
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Net revenue |
|
$ |
39,559 |
|
|
$ |
32,928 |
|
|
$ |
71,147 |
|
|
$ |
56,345 |
|
Cost of revenue |
|
|
9,534 |
|
|
|
7,947 |
|
|
|
17,561 |
|
|
|
12,798 |
|
Gross profit |
|
|
30,025 |
|
|
|
24,981 |
|
|
|
53,586 |
|
|
|
43,547 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Sales and marketing |
|
|
13,165 |
|
|
|
12,431 |
|
|
|
25,381 |
|
|
|
22,189 |
|
General and administrative |
|
|
19,654 |
|
|
|
14,546 |
|
|
|
37,320 |
|
|
|
27,713 |
|
Research and development |
|
|
2,792 |
|
|
|
1,747 |
|
|
|
5,062 |
|
|
|
3,774 |
|
Total operating expenses |
|
|
35,611 |
|
|
|
28,724 |
|
|
|
67,763 |
|
|
|
53,676 |
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
(5,586 |
) |
|
|
(3,743 |
) |
|
|
(14,177 |
) |
|
|
(10,129 |
) |
|
|
|
|
|
|
|
|
|
Other (income) expenses: |
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
294 |
|
|
|
1,212 |
|
|
|
84 |
|
|
|
1,777 |
|
Fair value adjustment of contingent consideration |
|
|
(2,304 |
) |
|
|
(5,010 |
) |
|
|
(2,974 |
) |
|
|
(2,440 |
) |
Other (income) loss |
|
|
(289 |
) |
|
|
827 |
|
|
|
(620 |
) |
|
|
723 |
|
Total other (income) expenses |
|
|
(2,299 |
) |
|
|
(2,971 |
) |
|
|
(3,510 |
) |
|
|
60 |
|
|
|
|
|
|
|
|
|
|
Loss before income taxes |
|
$ |
(3,287 |
) |
|
$ |
(772 |
) |
|
|
(10,667 |
) |
|
|
(10,189 |
) |
Provision for income taxes
(benefit) |
|
|
(401 |
) |
|
|
(439 |
) |
|
|
(975 |
) |
|
|
(756 |
) |
Net loss |
|
$ |
(2,886 |
) |
|
$ |
(333 |
) |
|
$ |
(9,692 |
) |
|
$ |
(9,433 |
) |
Weighted average common
stock – basic and diluted |
|
|
22,704,723 |
|
|
|
19,792,286 |
|
|
|
22,587,022 |
|
|
|
19,693,216 |
|
Net loss per share – basic and
diluted |
|
$ |
(0.13 |
) |
|
$ |
(0.02 |
) |
|
$ |
(0.43 |
) |
|
$ |
(0.48 |
) |
ORTHOPEDIATRICS CORP.CONDENSED
CONSOLIDATED STATEMENTS OF CASH
FLOWS(Unaudited)(In Thousands) |
|
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
|
2022 |
|
OPERATING ACTIVITIES |
|
|
Net loss |
|
$ |
(9,692 |
) |
|
$ |
(9,433 |
) |
Adjustments to reconcile net
loss to net cash used in operating activities: |
|
|
|
|
Depreciation and amortization |
|
|
7,928 |
|
|
|
6,292 |
|
Stock-based compensation |
|
|
5,415 |
|
|
|
3,296 |
|
Fair value adjustment of contingent consideration |
|
|
(2,974 |
) |
|
|
(2,440 |
) |
Accretion of acquisition installment payable |
|
|
812 |
|
|
|
1,545 |
|
Deferred income taxes |
|
|
(975 |
) |
|
|
(756 |
) |
Changes in certain operating current assets and liabilities: |
|
|
|
|
Accounts receivable – trade |
|
|
(8,964 |
) |
|
|
(6,614 |
) |
Inventories |
|
|
(11,860 |
) |
|
|
(10,905 |
) |
Prepaid expenses and other current assets |
|
|
72 |
|
|
|
557 |
|
Accounts payable – trade |
|
|
9,724 |
|
|
|
5,298 |
|
Accrued expenses and other liabilities |
|
|
1,325 |
|
|
|
1,133 |
|
Other |
|
|
(1,645 |
) |
|
|
(340 |
) |
Net cash used in operating
activities |
|
|
(10,834 |
) |
|
|
(12,367 |
) |
|
|
|
|
|
INVESTING ACTIVITIES |
|
|
|
|
Acquisition of MD Ortho, net
of cash acquired |
|
|
— |
|
|
|
(8,360 |
) |
Acquisition of Medtech |
|
|
(3,097 |
) |
|
|
— |
|
Sale of short-term marketable
securities |
|
|
72,347 |
|
|
|
31,600 |
|
Purchase of short-term
marketable securities |
|
|
(44,600 |
) |
|
|
— |
|
Purchases of property and
equipment |
|
|
(10,563 |
) |
|
|
(9,465 |
) |
Net cash provided by investing
activities |
|
|
14,087 |
|
|
|
13,775 |
|
|
|
|
|
|
FINANCING ACTIVITIES |
|
|
|
|
Proceeds from issuance of debt
with affiliate |
|
|
— |
|
|
|
31,000 |
|
Installment payment for
ApiFix |
|
|
(2,000 |
) |
|
|
(3,234 |
) |
Proceeds from exercise of
stock options |
|
|
— |
|
|
|
42 |
|
Payments on mortgage
notes |
|
|
(71 |
) |
|
|
(67 |
) |
Net cash (used in) provided by
financing activities |
|
|
(2,071 |
) |
|
|
27,741 |
|
|
|
|
|
|
Effect of exchange rate
changes on cash, cash equivalents and restricted cash |
|
|
(335 |
) |
|
|
400 |
|
|
|
|
|
|
NET INCREASE IN CASH, CASH
EQUIVALENTS AND RESTRICTED CASH |
|
|
847 |
|
|
|
29,549 |
|
|
|
|
|
|
Cash, cash equivalents and
restricted cash, beginning of period |
|
$ |
10,462 |
|
|
$ |
9,006 |
|
Cash, cash equivalents and
restricted cash, end of period |
|
$ |
11,309 |
|
|
$ |
38,555 |
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURES |
|
|
|
|
Cash paid for interest |
|
$ |
11 |
|
|
$ |
60 |
|
Transfer of instruments from
property and equipment to inventory |
|
$ |
367 |
|
|
$ |
(130 |
) |
Issuance of common shares to
acquire MD Ortho |
|
$ |
— |
|
|
$ |
9,707 |
|
Issuance of common shares for
ApiFix installment |
|
$ |
6,178 |
|
|
$ |
10,410 |
|
Issuance of common shares to
acquire MedTech |
|
$ |
2,274 |
|
|
$ |
— |
|
Right-of-use assets obtained
in exchange for lease liabilities |
|
$ |
293 |
|
|
$ |
116 |
|
ORTHOPEDIATRICS CORP.NET REVENUE BY
GEOGRAPHY AND PRODUCT
CATEGORY(Unaudited)(In
Thousands) |
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
Product sales by geographic location: |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
U.S. |
|
$ |
29,587 |
|
|
$ |
24,960 |
|
|
$ |
53,388 |
|
|
$ |
43,148 |
|
International |
|
|
9,972 |
|
|
|
7,968 |
|
|
|
17,759 |
|
|
|
13,197 |
|
Total |
|
$ |
39,559 |
|
|
$ |
32,928 |
|
|
$ |
71,147 |
|
|
$ |
56,345 |
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
Product sales by
category: |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Trauma and deformity |
|
$ |
27,514 |
|
|
$ |
22,568 |
|
|
$ |
50,909 |
|
|
$ |
39,084 |
|
Scoliosis |
|
|
10,893 |
|
|
|
9,421 |
|
|
|
17,966 |
|
|
|
15,404 |
|
Sports medicine/other |
|
|
1,152 |
|
|
|
939 |
|
|
|
2,272 |
|
|
|
1,857 |
|
Total |
|
$ |
39,559 |
|
|
$ |
32,928 |
|
|
$ |
71,147 |
|
|
$ |
56,345 |
|
ORTHOPEDIATRICS CORP.RECONCILIATION OF NET
LOSS TO NON-GAAP ADJUSTED
EBITDA(Unaudited)(In
Thousands) |
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Net loss |
|
$ |
(2,886 |
) |
|
$ |
(333 |
) |
|
$ |
(9,692 |
) |
|
$ |
(9,433 |
) |
Interest expense, net |
|
|
294 |
|
|
|
1,212 |
|
|
|
84 |
|
|
|
1,777 |
|
Other (income) expense |
|
|
(289 |
) |
|
|
827 |
|
|
|
(620 |
) |
|
|
723 |
|
Provision for income taxes (benefit) |
|
|
(401 |
) |
|
|
(439 |
) |
|
|
(975 |
) |
|
|
(756 |
) |
Depreciation and amortization |
|
|
4,080 |
|
|
|
3,331 |
|
|
|
7,928 |
|
|
|
6,292 |
|
Stock-based compensation |
|
|
3,303 |
|
|
|
1,770 |
|
|
|
5,415 |
|
|
|
3,296 |
|
Fair value adjustment of contingent consideration |
|
|
(2,304 |
) |
|
|
(5,010 |
) |
|
|
(2,974 |
) |
|
|
(2,440 |
) |
Acquisition related costs |
|
|
199 |
|
|
|
505 |
|
|
|
199 |
|
|
|
709 |
|
Nonrecurring Pega conversion fees |
|
|
— |
|
|
|
— |
|
|
|
277 |
|
|
|
— |
|
Minimum purchase commitment cost |
|
|
276 |
|
|
|
240 |
|
|
|
576 |
|
|
|
341 |
|
Adjusted EBITDA |
|
$ |
2,272 |
|
|
$ |
2,103 |
|
|
$ |
218 |
|
|
$ |
509 |
|
ORTHOPEDIATRICS CORP.RECONCILIATION OF
DILUTED LOSS PER SHARE TO NON-GAAP ADJUSTED DILUTED LOSS PER
SHARE(Unaudited) |
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Loss per share, diluted
(GAAP) |
|
$ |
(0.13 |
) |
|
$ |
(0.02 |
) |
|
$ |
(0.43 |
) |
|
$ |
(0.48 |
) |
Accretion of interest attributable to acquisition installment
payable |
|
|
0.02 |
|
|
|
0.06 |
|
|
|
0.04 |
|
|
|
0.08 |
|
Fair value adjustment of contingent consideration |
|
|
(0.10 |
) |
|
|
(0.25 |
) |
|
|
(0.13 |
) |
|
|
(0.12 |
) |
Acquisition related costs |
|
|
0.01 |
|
|
|
0.03 |
|
|
|
0.01 |
|
|
|
0.04 |
|
Nonrecurring Pega conversion fees |
|
|
— |
|
|
|
— |
|
|
|
0.01 |
|
|
|
— |
|
Minimum purchase commitment cost |
|
|
0.01 |
|
|
|
0.01 |
|
|
|
0.03 |
|
|
|
0.02 |
|
Loss per share, diluted
(non-GAAP) |
|
$ |
(0.19 |
) |
|
$ |
(0.17 |
) |
|
$ |
(0.47 |
) |
|
$ |
(0.46 |
) |
OrthoPediatrics (NASDAQ:KIDS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
OrthoPediatrics (NASDAQ:KIDS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024